Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.78 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NCF1 | P14598 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329323 | 1.00 | HRH3 (0.78) | HRH3HRH4ALDH1A1LMNAPOLB | |
| Hydrochloric Acid SCHEMBL6968666 | 0.98 | HRH3 (0.75) | HRH3HRH4ALDH1A1LMNAPOLB | |
| SCHEMBL11852 | 0.98 | HRH3 (0.74) | HRH3HRH4ALDH1A1LMNAPOLB | |
| SCHEMBL1046331 | 0.93 | ALDH1A1 (0.70) | HRH3HRH4ALDH1A1LMNAPOLB | |
| SCHEMBL13215736 | 0.93 | ALDH1A1 (0.70) | HRH3HRH4ALDH1A1LMNAPOLB | |
| SCHEMBL1045595 | 0.91 | ALDH1A1 (0.74) | HRH3HRH4ALDH1A1LMNAPOLB | |
| SCHEMBL1045984 | 0.91 | ALDH1A1 (0.74) | HRH3HRH4ALDH1A1LMNAPOLB | |
| SCHEMBL7989530 | 0.89 | LMNA (0.83) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL11356824 | 0.89 | LMNA (0.83) | HRH3ALDH1A1LMNAPOLBCXCR4 | |
| SCHEMBL1045922 | 0.89 | LMNA (0.83) | HRH3ALDH1A1LMNAPOLBCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| EP-3480186-B1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022114905-A1 | NOVEL JAK-SPECIFIC INHIBITOR COMPOUND AND METHOD FOR PREPARING SAME | 주식회사한국파마 | 2022-06-02 | — | — | WO | disclosed |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| EP-3459936-B1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-04-27 | — | — | EP | disclosed |
| EP-3601287-B1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIV PALACKEHO (CZ) | 2021-12-15 | — | — | EP | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1771429-A1 | NEW BENZOYL UREA DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-11 | — | — | EP | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2006010966-A1 | NEW BENZOYL UREA DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005087726-A1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | WO | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | HRH3 4374/4885HRH4 4308/4885ALDH1A1 1243/4885 |
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | HRH3 4828/4885HRH4 4490/4885ALDH1A1 2551/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | HRH3 2177/4885HRH4 1983/4885ALDH1A1 398/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | HRH3 4374/4885HRH4 4308/4885ALDH1A1 1243/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | HRH3 1767/4885HRH4 2179/4885ALDH1A1 2897/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | HRH3 137/4885HRH4 42/4885ALDH1A1 4356/4885 |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | HRH3 951/4885HRH4 507/4885ALDH1A1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.